Skip Navigation



Journal of the National Cancer Institute Advance Access published online on October 27, 2009
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djp372
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Coupé, V. M. H.
Right arrow Articles by Berkhof, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coupé, V. M. H.
Right arrow Articles by Berkhof, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

CORRESPONDENCE

Re: Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands

Veerle M. H. Coupé, Chris J. L. M. Meijer, Johannes Berkhof

Affiliations of authors: Department of Epidemiology and Biostatistics (VMHC, JB) and Department of Pathology (CJLMM), VU University Medical Centre, Amsterdam, the Netherlands

Correspondence to: Veerle M. H. Coupé, PhD, Department of Epidemiology and Biostatistics, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, the Netherlands (e-mail: v.coupe@vumc.nl).

The first 10% of the full text of this article appears below.

de Kok et al. (1) recently reported the cost-effectiveness of human papillomavirus vaccination in the Netherlands and argued that human papillomavirus vaccination is not a cost-effective preventive measure in the Netherlands. They calculated a discounted (annual rate 3%) incremental cost-effectiveness . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?